JP2019535292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535292A5 JP2019535292A5 JP2019528055A JP2019528055A JP2019535292A5 JP 2019535292 A5 JP2019535292 A5 JP 2019535292A5 JP 2019528055 A JP2019528055 A JP 2019528055A JP 2019528055 A JP2019528055 A JP 2019528055A JP 2019535292 A5 JP2019535292 A5 JP 2019535292A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- modified protein
- signaling
- protein according
- signal transduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000035118 modified proteins Human genes 0.000 claims description 43
- 108091005573 modified proteins Proteins 0.000 claims description 43
- 230000019491 signal transduction Effects 0.000 claims description 23
- 230000011664 signaling Effects 0.000 claims description 21
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 16
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 230000004807 localization Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 102000014400 SH2 domains Human genes 0.000 claims description 6
- 108050003452 SH2 domains Proteins 0.000 claims description 6
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 6
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 6
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 6
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 102000034285 signal transducing proteins Human genes 0.000 claims description 4
- 108091006024 signal transducing proteins Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims description 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 claims description 2
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 claims description 2
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 claims description 2
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1620070.1 | 2016-11-28 | ||
| GBGB1620070.1A GB201620070D0 (en) | 2016-11-28 | 2016-11-28 | Signal transduction modifying protein |
| PCT/GB2017/053555 WO2018096361A1 (en) | 2016-11-28 | 2017-11-27 | Signal transduction modifying protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535292A JP2019535292A (ja) | 2019-12-12 |
| JP2019535292A5 true JP2019535292A5 (enExample) | 2020-11-12 |
Family
ID=58073102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528055A Withdrawn JP2019535292A (ja) | 2016-11-28 | 2017-11-27 | シグナル伝達改変タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190309046A1 (enExample) |
| EP (1) | EP3544995A1 (enExample) |
| JP (1) | JP2019535292A (enExample) |
| GB (1) | GB201620070D0 (enExample) |
| WO (1) | WO2018096361A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| EP3810753A1 (en) * | 2018-06-19 | 2021-04-28 | Autolus Limited | Cell |
| CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术(广州)有限公司 | Shp-1敲除的t细胞及其构建方法 |
| JP7602475B2 (ja) * | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびcarの調節因子を含む組成物および方法 |
| CA3157416A1 (en) * | 2019-11-14 | 2021-05-20 | George Coukos | Compositions and methods for immunotherapy |
| CN113105554B (zh) * | 2020-01-13 | 2022-07-26 | 广东泰禾医药科技有限公司 | 一种抗肿瘤融合蛋白及其制法和应用 |
| CN115427451A (zh) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途 |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| WO2022235832A1 (en) * | 2021-05-06 | 2022-11-10 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| GB201514874D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
-
2016
- 2016-11-28 GB GBGB1620070.1A patent/GB201620070D0/en not_active Ceased
-
2017
- 2017-11-27 EP EP17812034.1A patent/EP3544995A1/en not_active Withdrawn
- 2017-11-27 US US16/463,258 patent/US20190309046A1/en not_active Abandoned
- 2017-11-27 WO PCT/GB2017/053555 patent/WO2018096361A1/en not_active Ceased
- 2017-11-27 JP JP2019528055A patent/JP2019535292A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535292A5 (enExample) | ||
| JP7306731B2 (ja) | ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾 | |
| JP7611836B2 (ja) | 抗原特異的t細胞の同定のための組成物と方法 | |
| Adachi et al. | Distinct germinal center selection at local sites shapes memory B cell response to viral escape | |
| Bae et al. | Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling | |
| JP2024069663A (ja) | 腫瘍特異的t細胞受容体を得る方法 | |
| JP2016538854A5 (enExample) | ||
| JP7388798B2 (ja) | Suv39h1を欠損する免疫細胞 | |
| US20250041412A1 (en) | Transmembrane neoantigenic peptides | |
| CN105131126B (zh) | 用于治疗恶性肿瘤的嵌合抗原受体及其制备方法与应用 | |
| JP2019530456A (ja) | 癌の新規抗原性シグネチャーを標的としたcar療法のためのユニバーサルプラットフォーム | |
| RU2016124278A (ru) | Клетка | |
| KR20160127130A (ko) | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) | |
| JP2016538855A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| CN112912507A (zh) | 甲病毒新抗原载体和干扰素抑制剂 | |
| Li et al. | Rabies virus phosphoprotein interacts with ribosomal protein L9 and affects rabies virus replication | |
| Torikai et al. | A novel HLA-A* 3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene | |
| Vauchy et al. | CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes | |
| JP2022553409A (ja) | 免疫細胞制御用キメラポリペプチド | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2019535292A (ja) | シグナル伝達改変タンパク質 | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| Tang et al. | p53 is an important regulator of CCL2 gene expression | |
| JP2022527813A (ja) | Magea1特異的t細胞受容体およびその使用 |